Skip to Main Content
+
AASLD/IDSA HCV GUIDANCE PANEL: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932, 2015. Updated regularly and available at http://www.hcvguidelines.org. Accessed September 22, 2016.  [PubMed: 26111063]
+
Carbone  M, Neuberger  JM: Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 60:210, 2014.  [PubMed: 24084655]
+
European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167, 2012.  [PubMed: 22436845]
+
European Association for the Study of the Liver: EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:971, 2015.
+
European Association for the Study of the Liver: EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 2016 in press. Available at http://dx.doi.org/10.1016/j. jhep.2016.09.001. Accessed September 22, 2016.
+
Lok  ASG  et al: Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 63:284, 2016.  [PubMed: 26566246]
+
Manns  MP  et al: AASLD Practice Guidelines: Diagnosis and management of autoimmune hepatitis. Hepatology 51;2193, 2010.
+
Pawlotsky  J-M  et al: From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62:S87, 2015.  [PubMed: 25920094]
+
Terrault  N  et al: AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:261, 2016.  [PubMed: 26566064]
+
Wedemeyer  H  et al: Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364:322, 2011.  [PubMed: 21268724]

ADDITIONAL ONLINE BIBLIOGRAPHY

+
Charlton  M  et al: Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:649, 2015.  [PubMed: 25985734]
+
Chhatwal  J  et al: Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 64:1442, 2016.  [PubMed: 27015107]
+
Curry  MP  et al: Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618, 2015.  [PubMed: 26569658]
+
Czaja  AJ: Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 51:161, 2009.  [PubMed: 19446908]
+
Dienstag  JL: Hepatitis B virus infection. N Engl J Med 359:1486, 2008.  [PubMed: 18832247]
+
Feld  JJ  et al: Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373:2599, 2015.  [PubMed: 26571066]
+
Foster  GR  et al: Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608, 2015.  [PubMed: 26575258]
+
Foster  GR  et al: Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:1224, 2016.  [PubMed: 26829205]
+
Heller  T  et al: Long-term therapy of chronic delta hepatitis ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.